Associated Papers
First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.
Li W et al.
Signal Transduction and Targeted Therapy, 2024
39489747 (PubMed )
Supplement: 41392_2024_2006_MOESM1_ESM.docx
Select a paper to view details